Andreas Blom new CFO in Toleranzia AB

18 May - 2016

Toleranzia AB (Toleranzia) announces that its Chief Financial Officer (CFO), Håkan Sterner, will retire May 24, 2016. Toleranzia has recruited Andreas Blom as Sterner’s successor. Blom will assume the CFO position May 25, 2016.

Andreas Blom, Toleranzias incoming CFO, has an MBA and a background in EY. Blom is CFO of the portfolio at GU Ventures AB and has extensive experience in accounting and overall financial management of companies in the early stages of development, as well as listed companies. Blom holds a small percentage of shares and warrants of series TO 1 in Toleranzia.

– I want to thank Håkan for his work during his time at Toleranzia –  Håkan has meant a lot for us, not least in connection with the listing on AktieTorget. At the same time, I want to welcome Andreas as a colleague and a member of the management team. Andreas has extensive experience and has good knowledge of Toleranzia through his work at GU Ventures. We have an important period ahead of us and I look forward to working together with Andreas! says Charlotte Fribert, CEO of Toleranzia.

For further information, please contact:
Charlotte Fribert – CEO
Phone: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com

About the company
Toleranzia AB (556877-2866) has developed a platform technology for treatment of autoimmune diseases. The company´s main project is directed towards an autoimmune neuromuscular disease, myasthenia gravis, with a significant need for an effective treatment and an extensive market potential, for which Toleranzia has been granted Orphan Drug Designation in both EU and US. The platform technology enables development of therapies that target the root cause of the disease – not just the symptoms, which is the mainstay of current treatment. In addition to myasthenia gravis, the platform technology has been evaluated in three further disease indications – rheumatoid arthritis, multiple sclerosis and type 1 diabetes, where positive treatment effects have been obtained in disease-relevant animal models. Toleranzia was founded by researchers at the University of Gothenburg. The company has operations at the Biotech center in Gothenburg. Further reading at: www.toleranzia.com.